You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》瑞信首予心通医疗(02160.HK)「跑赢大市」评级 目标价21元
瑞信发表研究报告,首予心通医疗-B(02160.HK)「跑赢大市」评级,目标价21元。该行称,心通医疗获母企微创医疗(00853.HK)强大支持,心通医疗销售团队可运用微创医疗销售团队渗透内地市场。在中国之外市场,心通医疗销售及市务团队可受惠微创医疗全球品牌影响力。

报告称,心通医疗具综合产品线,第二代TAVR(经导管主动瓣膜置换术)料快将获批。长远而言,料VitaFlow II成为板块重大收入来源,而第二代设备亦降低医生进行TAVR手术的风险。

该行料心通医疗今年亏损收窄至8,310万元人民币,明年转赚5,120万元人民币,2023年纯利进一步增至近2.59亿元人民币,对应今年每股亏损料4分人民币,料明後两年每股纯利分别2分及11分人民币。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account